Does AXA Health Cover Wegovy — and What Are Your Options?

Does AXA Health typically pay for Wegovy?

This is the question most people searching this topic genuinely want answered, so let's be direct. Private medical insurance in the UK is primarily designed to cover diagnosis and treatment of acute conditions. Weight management (including prescription medicines like Wegovy) sits in a different category for most insurers, and AXA Health is no exception to that general pattern.

Whether your specific AXA Health policy covers Wegovy depends on several things: the tier of cover you hold, whether a weight-management or chronic-condition benefit has been added, and whether your GP or specialist has framed your situation around a qualifying comorbidity such as type 2 diabetes or cardiovascular disease rather than weight management alone. Some enhanced corporate plans include access to weight-management programmes; standard individual policies often exclude them.

The only way to get a definitive answer is to read your policy schedule carefully and, if it is unclear, call AXA Health's member services line. What you are looking for is whether your policy lists weight-management medicines or GLP-1 receptor agonists as a covered benefit, and whether prior authorisation from a specialist is required. A GP referral letter setting out the clinical rationale may strengthen a claim in borderline cases, but there are no guarantees. If you are feeling frustrated at having to chase this through admin when you just want to get started, that frustration is entirely reasonable, and it is something a lot of people in your position describe.

What happens if your AXA policy does not cover Wegovy?

If cover is excluded or your claim is unsuccessful, a private prescription through a regulated pharmacy route is the practical alternative. You do not need a referral, and there is no waiting list, the process starts with a clinical consultation, after which a GPhC-registered Independent Prescriber reviews your answers personally, the same day.

It is worth understanding what a legitimate private cost covers. Because Wegovy is a prescription-only medicine, any lawful supply includes the prescriber's clinical assessment, the prescription itself, and ongoing clinical oversight, not just the medicine. Providers who advertise dramatically low prices often exclude one or more of these components. Our guide to Wegovy costs in the UK sets out what the market looks like and what a single transparent price should include, without any hidden fees.

For context: Eli Lilly's September 2025 list-price increase for Mounjaro prompted broader reporting on GLP-1 medicine pricing. Wegovy prices in the private market vary by dose, typically ranging from around £149 to £375 per month depending on provider and strength, though these figures shift, so treat them as a rough guide rather than a fixed market rate. NHS guidance on semaglutide covers what the medicine is and how it works, which is useful background before any consultation.

What does Wegovy actually involve, and who is it licensed for?

Wegovy contains semaglutide, which works on GLP-1 receptors involved in appetite signalling and blood sugar regulation. It slows how quickly food leaves the stomach and increases the sense of fullness after eating. It is a once-weekly subcutaneous injection, self-administered using a pre-filled pen.

Treatment starts at a low dose (0.25mg) and is increased gradually by the prescriber, typically in four-week steps, up to a maintenance dose of 2.4mg, or, since MHRA approval in April 2026, up to the new 7.2mg dose via a dedicated single-dose pen for eligible adults. If you want to understand how the starting phase works in practice, our guide to Wegovy 1 walks through what to expect during the initial titration period. In the STEP 1 clinical trial (68 weeks, semaglutide 2.4mg vs placebo), participants experienced an average body weight reduction of around 15%, according to the published findings in the New England Journal of Medicine.

The licensed eligibility criteria for Wegovy are a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Wegovy is not licensed for people under 18, and is not recommended during pregnancy, breastfeeding, or when trying to conceive. A prescriber assesses the full picture, BMI is one factor, not the only one.

For a broader look at how semaglutide is used in weight management, the semaglutide overview covers the mechanism, the trial evidence, and what the titration schedule looks like in practice. If you want to read about what comes after the starting phase, our guide to Wegovy 2 covers the dose increases and what to expect as treatment progresses. If you're curious about the injection schedule specifically, the guidance on spacing Wegovy shots is a useful read before you start.

Is Wegovy available on the NHS, and how does the private route compare?

Wegovy is available on the NHS through specialist weight management services, under NICE guidance (TA875). NHS access involves strict eligibility criteria, referral through your GP, and in most areas a meaningful wait. The NICE recommendation for semaglutide specifies it should be used for a maximum of two years and within a multidisciplinary specialist service, the NHS route is comprehensive but not fast.

A private prescription through a regulated online pharmacy operates independently of that system. There is no referral needed, no waiting list, and clinical review happens the same day. The weight-loss treatment overview sets out the options clearly if you are weighing up which route suits your situation. When you're ready to speak to someone clinical rather than read more pages, you can speak to our prescribers through a free consultation, no obligation, and the review is done by a named clinician, not a bot.